Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen

Bibliography

• TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Oncol. (1996) 14:1756–1764.
   Google Scholar
• KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. (1999) 17:2506–2513.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, DE WIT R, BERRY WR et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl. J. Med. (2004) 351:1502-1512 This reports the first chemotherapy regimen approved for the treatment of metastatic prostate cancer which also showed a survival benefit.
   Google Scholar
• PETRYLAK DP, TANGEN CM, HUSSAIN MH et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl. I Med. (2004) 351:1513–1520.
   PubMed Web of Science ®Google Scholar
• BURCH PA, CROGHAN GA, GASTINEAU DA et al.: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase II trial. Prostate (2004) 60:197–204.
   PubMed Web of Science ®Google Scholar
• KYLSTRA JW, NEMUNAITIS J, SMALL EJ, JONES LA: A placebo-controlled Phase III trial of immunotherapy (APC8015, Provenge®) for androgen independent prostate cancer (AIPC): Evidence that Gleason Score predicts immunologic as well as clinical responses to therapy. Proc. Am. Assoc. Cancer Res. (2004) 45:? Abstract 1408.
   Google Scholar
• SIMONS J, HIGANO C, CORMAN J et al.: A Phase I/II study of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:166 Abstract 667.
   Google Scholar
• ••An interesting study of GM-CSFused in concert with a prostate cancer cell line vaccine.
   Google Scholar
• SIMONS J, NELSON W, NEMUNAITIS J et al.: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:183a Abstract 729.
   Google Scholar
• •Results of a phase II trial of a prostate cancer cell line vaccine demonstrating an antitumor effect.
   Google Scholar
• SLOVIN SF, RAGUPATHI G, MUSSELLI C et al.: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-0-serine/ threonine conjugate vaccine. J. Oncol. (2003) 21:4292–4298.
   Web of Science ®Google Scholar
• SLOVIN S, RAGUPATHI G, CLARKE T et al.: Multivalency in a Phase II prostate cancer (PC) vaccine trial: Are more antigens better? Proc. Am. Soc. Clin. Oncol. (2003) 22:167 Abstract 671.
   Google Scholar
• SLOVIN SF, RAGUPATHI G, MUSSELLI C et al: Thomsen-Friedenreich. Cancer Immun. Immunother. In press.
   Google Scholar
• KAUFMAN HL, WANG W, MANOLA J et al.: Prime/boost vaccination using poxviruses expressing PSA in DO prostate cancer: preliminary results of ECOG 7897, a randomized Phase II clinical trial. Proc. Am. Soc. Clin. Oncol. (2002) 21:4a Abstract 12.
   Google Scholar
• SCHER HI, EISENBERGER M, D'AMICO AV et al: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. (2004) 22:537–556.
   PubMed Web of Science ®Google Scholar
• ••This paper represents a consensus byauthorities in prostate cancer clinical trial development which addresses the establishment of appropriate clinical trial end points.
   Google Scholar
• HINKLE GH, BURGERS JK, NEAL CE et al.: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 83:739–747.
   PubMed Web of Science ®Google Scholar
• GHOSH H, HESTON WDW: Tumor target Prostate Specific Membrane Antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. (2004) 91:528–539.
   PubMed Web of Science ®Google Scholar
• SCHULKE N, VARLAMOVA OA, DONOVAN GP et al.: The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. USA (2003) 100:12590–12595.
   PubMed Web of Science ®Google Scholar
• SILVER DA, PELLICER I, FAIR WR et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. (1997) 3:81–85.
   PubMed Web of Science ®Google Scholar
• SU SL, HUANG IP, FAIR WR et al: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. (1995) 55:1441–1443.
   PubMed Web of Science ®Google Scholar
• CHANG SS, REUTER VE, HESTON WD, GAUDIN PB: Metastatic renal cell carcinoma neovasculature expresses prostate specific membrane antigen. Urology (2001) 57:801–805.
   PubMed Web of Science ®Google Scholar
• CHANG SS, REUTER VE, HESTON WD et al: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192–3198.
   PubMed Web of Science ®Google Scholar
• •A study suggeting a pivotal role for PSMA in neovasculature.
   Google Scholar
• DIVGI CR, BANDER NH, SCOTT AM et al.: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. (1998) 4:2729–3279.
   PubMed Web of Science ®Google Scholar
• CHANG SS, O'KEEFE DS, BACICH DJ et al: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. (1999) 5:2674–2681.
   PubMed Web of Science ®Google Scholar
• BANDER NH, TRABULSI EJ, KOSTAKOGLU L et al: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. (2003) 170:1717–1721.
   PubMed Web of Science ®Google Scholar
• ••This describes a new monoclonalantibody which targets the external domain of PSMA.
   Google Scholar
• SMITH-JONES PM, VALLABAHAJOSULA S, GOLDSMITH SJ et al: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. (2000) 60:5237–5243.
   PubMed Web of Science ®Google Scholar
• MILOWSKY MI, NANUS DM, KOSTAKOGLU L et al: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22:2522–2531.
   PubMed Web of Science ®Google Scholar
• NANUS DM, MILOWSKY MI, KOSTAKOGLU L et al: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. (2003) 170:S84–S88.
   Web of Science ®Google Scholar
• TJOA BA, SIMMONS SJ, ELGAMA A et al: Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate (1999) 4:125–129.
   Google Scholar
• GONG MC, LATOUCHE JB, KRAUSE Aet al: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1:123–127.
   PubMedGoogle Scholar
• O'KEEFE DS, UCHIDA A, BACICH D et al: Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate (2000) 45:149–157.
   PubMed Web of Science ®Google Scholar
• GONG MC, CHANG SS, WATT F et al: Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol. Urol. (2000) 4:217–222.
   PubMedGoogle Scholar
• UCHIDA A, O'KEEFE DS, BACICH DJ et al.: Li vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology (2001) 85:132–139.
   Google Scholar
• MINCHEFF M, ALTANKOVA I, ZOUBAK S et al.: LI vivo transfection and/ or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer - changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Grit. Rev Oncol. Hematol. (2001) 39:125–132.
   PubMed Web of Science ®Google Scholar
• LU J, CELLIS E: Recognition of prostatetumor cell by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. (2002) 62:5807–5812.
   PubMed Web of Science ®Google Scholar
• KURATSUKURI K, SONE T, WANG CT et al.: Inhibition of prostate specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. bit.j Cancer (2002) 102:244–249.
   PubMed Web of Science ®Google Scholar
• MINCHEFF M, ZOUBAK S, ALTANKOVA I et al.: Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. (2003) 10:907–917.
   PubMed Web of Science ®Google Scholar
• MINCHEFF M, TCHAKAROV S, ZOUBAK S et al.: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur. Urol. (2000) 38:208–217.
   PubMed Web of Science ®Google Scholar
• HORIGUCHI Y, NUKAYA I, OKAZAWA K et al.: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. (2002) 8:3885–3892.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate (2000) 43:59–62.
   PubMed Web of Science ®Google Scholar
• ANILKUMAR G, RAJASEKARAN SA, WANG S et al: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. (2003) 63:2645–2648.
   PubMed Web of Science ®Google Scholar
• BACICH DJ, PINTO JT, TONG WP, HESTON WD: Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/ NAALADase/folate hydrolase. Mamm. Genome (2001) 12:117–123.
   PubMed Web of Science ®Google Scholar
• YAO R, SCHNEIDER E, RYAN TJ et al: Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc. Natl. Acad. Sci. USA (1996) 93:10134–10138.
   PubMed Web of Science ®Google Scholar
• TASCH J, GONG M, SADELAIN M, HESTON WD: A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Grit. Rev Lnmunol. (2001) 21:249–261.
   Google Scholar
• LIU H, RAJASEKARAN AK, MOY P et al.: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. (1998) 58:4055–4060.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF: Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematol. Oncol. Clin. North. Am. (2001) 15:477–496
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, SCHER HI: Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center. Semin. Oncol. (1999) 26:448–454.
   PubMed Web of Science ®Google Scholar
• WOLCHOK JD, GREGOR PD, NORDQUIST LT et al.: DNA vaccines: an active immunization strategy for prostate cancer. Sem. Oncol. (2003) 30:659–666.
   PubMed Web of Science ®Google Scholar
• GREGOR PD, WOLCHOK JD, FERRONE CR et al.: CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 22: 1700-1708.
   Google Scholar
• FONG L, RUEGG CL, BRICKSTEDT D et al.: Induction of tissue specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Cancer Res. (1999) 59:3102–3198.
   Google Scholar
• GARDNER JP, SLOVIN SF, MORRISSEY DM et al.: Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: preliminary findings of a Phase I safety/immunogenicity trial. Proc. Am. Soc. Clin. Onc. (2004) 23:184 Abstract 2584.
   Google Scholar
• GARDNER JP, DONOVAN GP, SCHUELKE N et al.: Active tumor immunotherapy using novel PSMA-based alphavirus and protein vaccines. Proc. Am. Assoc. Cancer Res. (2003) 44:1088 Abstract 4747.
   Google Scholar
• VELDERS MP, MCELHINEY S, CASSETTI MC et al.: Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavurus 16 E7 RNA. Cancer Res. (2001) 61:7861–7867.
   PubMed Web of Science ®Google Scholar
• DAVIS NL, CALEY IJ, BROWN KW et al.: Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. (2000) 74:371–378.
   PubMed Web of Science ®Google Scholar